ODD · ODDITY Tech Ltd. · Stock research

Current Thesis

ODDITY is a broken direct-to-consumer beauty compounder whose acquisition engine seized. IL MAKIAGE's paid-acquisition flywheel jammed on a customer-acquisition-cost (CPA) blowout tied to its largest ad partner, and Q1 2026 first orders collapsed 50% YoY. The stock crashed from a 52-week high of $77.83 to a $9.25 low, then nearly doubled to ~$18 and that bounce now sits above almost every post-print Street price target ($8–$12). The narrative here is a normalization hope, not an accelerating story; the whole re-rate is gated on the Q2 2026 print (~mid-August) proving CPA and first-order recovery. Until then this is a countertrend bounce into overhead crash-gap supply, and the setup is a pass for a momentum book.

Bullish and bearish views on ODDITY Tech Ltd.

The model's bull view on ODDITY Tech Ltd. (ODD), in brief: Q1 2026 (reported 2026-06-02): revenue $197.9M, -26% YoY better than the pre-announced ~-30% cut. The bear view: First orders -50% is a flywheel breaking, not a blip. Both cases follow in full.

Bull Case

• Q1 2026 (reported 2026-06-02): revenue $197.9M, -26% YoY better than the pre-announced ~-30% cut. Less-bad-than-feared is the first sequential-normalization datapoint the recovery camp is buying.
• Repeat orders only -15% vs first orders -50% (Q1 call). The installed base and reorder economics held; management attributes the miss to a technical ad-partner failure rather than eroding end demand.
• 2026-06-12: repurchased $50M face of 0% exchangeable notes due 2030 for $35M ~70 cents on the dollar, ~$15M accretive, cutting 2030 dilution and leverage. A balance-sheet-confidence signal and cash deployment near the lows.
• FY2026 guide: positive adjusted EBITDA even through the H1 acquisition air-pocket the model still throws off cash.
• Optionality stack: Methodiq telehealth-derm brand (launched 2025-11-18; 28 SKUs at ~$29–$59; Oddity Labs proprietary compounds), Brand 4 slated for 2026, plus Oddity Labs / Osmo AI molecule and scent work. SpoiledChild proves the new-brand playbook is real.
• Valuation reset: fair-value estimates cut from ~$40 to ~$8; ~$826M market cap with a sizeable net-cash cushion.

Bear Case

• First orders -50% is a flywheel breaking, not a blip. DTC models compound off new-customer cohorts; a lost H1 acquisition year pressures repeat revenue deep into 2027.
• Q2 2026 guide still points DOWN: revenue -25% to -30% YoY, adjusted EBITDA just $8–$10M. The next print does not yet mark the turn.
• Margin collapse: Q1 adjusted EBITDA margin -3.6% versus +19.5% a year earlier, with a $21.4M net loss versus $37.8M net income in Q1 2025. Profitability the core of the ODD long vanished in one quarter.
• The tape front-runs the fundamentals. At ~$18 the stock trades above the entire post-print PT cluster: Morgan Stanley $10, Barclays $8, Jefferies $10.25, Truist $12, Goldman at Sell, consensus a ~$9 Hold.
• Single-ad-partner dependency is a structural fragility the "technical issue" framing exposes, not a one-off.
• Theme drag: consumer-discretionary-rotation is MATURING, offering no thematic lift to a name with a broken model.

Setup & Price Structure

52-week range $9.25–$77.83; last around $17.88 (2026-07-03) on a ~$826M cap. The chart is an ~80% peak-to-trough crash followed by a near-double dead-cat / short-cover bounce off $9.25. Price is stretched relative to fundamentals sitting above the $8–$12 analyst target band rather than extended above a rising moving average, so there is no ACCELERATING momentum long to buy here. The rally is climbing into the supply left by the crash gap. This is the classic falling-knife trap: a name that looks "cheap after -80%" bought on normalization hope into a quarter still guided -25% to -30%. Constructive entries only belong on a confirmed first-order inflection, not on the bounce.

Catalyst Calendar (next 30 days)

• 2026-07-29 Annual General Meeting (board, auditor, governance votes). Dated but governance-only; low price impact.
• Ongoing Methodiq ramp datapoints and any Brand 4 launch detail (2026, undated).

Elapsed catalysts

• ~2026-08 (est., mid-month) Q2 2026 results. THE binary: first-order trend and CPA normalization either validate the bounce or send it back toward $9.25. Falls just outside the 30-day window (Q1 was reported late, on 2026-06-02). _(passed 43d ago)_

What Would Change Our Mind

• Turn constructive if: the Q2 print shows first orders inflecting (decline narrowing toward -20% or better) with CPA normalizing, and price holds the recovery shelf on the reaction.
• Turn / stay negative if: a weekly close below $13 abandons the post-crash recovery shelf and re-opens the $9.25 low, or the consumer-discretionary theme flips to SATURATED with no ODD-specific catalyst.
• Watch the leading indicator: first-order trend, not headline revenue revenue lags the acquisition funnel by a quarter.

Correlation Notes

Moves with digital-ad-dependent DTC / e-commerce names sensitivity runs through Meta/Google acquisition-funnel efficiency and CPA trends broadly. Beauty peers (e.l.f., Coty) frame the sector backdrop, but ODD's break is idiosyncratic (acquisition engine), not category-demand driven, so it can diverge sharply from the group. Elevated short interest and a modest float amplify mechanical countertrend squeezes, meaning part of the bounce is positioning rather than fundamentals.